35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The slow Wallerian degeneration (Wld S) protein protects injured axons from degeneration. This unusual chimeric protein fuses a 70–amino acid N-terminal sequence from the Ube4b multiubiquitination factor with the nicotinamide adenine dinucleotide–synthesizing enzyme nicotinamide mononucleotide adenylyl transferase 1. The requirement for these components and the mechanism of Wld S-mediated neuroprotection remain highly controversial. The Ube4b domain is necessary for the protective phenotype in mice, but precisely which sequence is essential and why are unclear. Binding to the AAA adenosine triphosphatase valosin-containing protein (VCP)/p97 is the only known biochemical property of the Ube4b domain. Using an in vivo approach, we show that removing the VCP-binding sequence abolishes axon protection. Replacing the Wld S VCP-binding domain with an alternative ataxin-3–derived VCP-binding sequence restores its protective function. Enzyme-dead Wld S is unable to delay Wallerian degeneration in mice. Thus, neither domain is effective without the function of the other. Wld S requires both of its components to protect axons from degeneration.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Axon degeneration mechanisms: commonality amid diversity.

          A wide range of insults can trigger axon degeneration, and axons respond with diverse morphology, topology and speed. However, recent genetic, immunochemical, morphological and pharmacological investigations point to convergent degeneration mechanisms. The principal convergence points - poor axonal transport, mitochondrial dysfunction and an increase in intra-axonal calcium - have been identified by rescuing axons with the slow Wallerian degeneration gene (Wld(S)) and studies with blockers of sodium or calcium influx. By understanding how the pathways fit together, we can combine our knowledge of mechanisms, and potentially also treatment strategies, from different axonal disorders.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene.

            Axons and their synapses distal to an injury undergo rapid Wallerian degeneration, but axons in the C57BL/WldS mouse are protected. The degenerative and protective mechanisms are unknown. We identified the protective gene, which encodes an N-terminal fragment of ubiquitination factor E4B (Ube4b) fused to nicotinamide mononucleotide adenylyltransferase (Nmnat), and showed that it confers a dose-dependent block of Wallerian degeneration. Transected distal axons survived for two weeks, and neuromuscular junctions were also protected. Surprisingly, the Wld protein was located predominantly in the nucleus, indicating an indirect protective mechanism. Nmnat enzyme activity, but not NAD+ content, was increased fourfold in WldS tissues. Thus, axon protection is likely to be mediated by altered ubiquitination or pyridine nucleotide metabolism.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Experiments on the Section of the Glossopharyngeal and Hypoglossal Nerves of the Frog, and Observations of the Alterations Produced Thereby in the Structure of Their Primitive Fibres

              A. Waller (1850)
                Bookmark

                Author and article information

                Journal
                J Cell Biol
                J. Cell Biol
                jcb
                The Journal of Cell Biology
                The Rockefeller University Press
                0021-9525
                1540-8140
                23 February 2009
                : 184
                : 4
                : 491-500
                Affiliations
                [1 ]Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, England, UK
                [2 ]Istituto di Biotecnologie Biochimiche, Università Politecnica delle Marche, 60131 Ancona, Italy
                [3 ]Centre for Neuroscience Research, University of Edinburgh, Edinburgh EH8 9JZ, Scotland, UK
                [4 ]Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche, e Farmacologiche and [5 ]Drug and Food Biotechnology Center, Università del Piemonte Orientale, 28100 Novara, Italy
                Author notes
                Correspondence to Michael Coleman: michael.coleman@ 123456bbsrc.ac.uk
                Article
                200807175
                10.1083/jcb.200807175
                2654131
                19237596
                271ef8d9-c1fd-4e8b-9776-fa2947c90ba5
                © 2009 Conforti et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

                History
                : 31 July 2008
                : 21 January 2009
                Categories
                Research Articles
                Report

                Cell biology
                Cell biology

                Comments

                Comment on this article